Epicutaneous Immunotherapy for Aeroallergen and Food Allergy

Current Treatment Options in Allergy

Volumn 1, Issue 1, 2014, Pages 68-78

  Senti, Gabriela ^a   von Moos, Seraina ^a   Kündig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Epicutaneous allergen specific immunotherapy; Food allergy; Respiratory allergy; Transcutaneous allergen specific immunotherapy

Indexed keywords

EID: 84910156056     PISSN: None     EISSN: 21963053     Source Type: Journal    
DOI: 10.1007/s40521-013-0003-8     Document Type: Review

References (72)

1. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–30. DOI: 10.1038/nri2262
2. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009;8(8):645–60. DOI: 10.1038/nrd2653
3. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177(4580):1572–3. DOI: 10.1016/S0140-6736(00)78276-6
4. Cox L, Cox L, Calderon MA, Calderon MA. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin. 2010;26(12):2723–33. DOI: 10.1185/03007995.2010.528647
5. Cox L, Nelson H, Lockey R, Calabria C, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–S55. DOI: 10.1016/j.jaci.2010.09.034
6. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558–62. DOI: 10.1016/S0091-6749(98)70271-4
7. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021–35. DOI: 10.1016/j.jaci.2006.02.040
8. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(2):319–25. DOI: 10.1016/j.jaci.2005.11.014
9. Henmar H, Lund G, Lund L, Petersen A, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol. 2008;153(3):316–23. DOI: 10.1111/j.1365-2249.2008.03710.x
10. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol. 2011;127(4):860–4. DOI: 10.1016/j.jaci.2011.02.016
11. Muller U, Akdis CA, Fricker M, Akdis M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101(6 Pt 1):747–54. DOI: 10.1016/S0091-6749(98)70402-6
12. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89–97. 97 e1-14. DOI: 10.1016/j.jaci.2010.11.029
13. Patel D, Couroux P, Hickey P, Salapatek AM, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131(1):103–9 e1-7. Large double-blind controlled clinical trial using Fel d 1–derived peptides for immunotherapy of cat dander allergic patients. These peptides are modified so they bind to most HLA class II molecules in the human population. Due to their short length and lack of tertiary structure, they do not bind IgE. The route chosen for peptide administration was intradermal injection.
14. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–55. First clinical trial to covalently link immunostimulatory CpG to an allergen. The number of injections using this adjuvant instead of alum could be reduced to 6. DOI: 10.1056/NEJMoa052916
15. Dubuske LM, Frew AJ, Horak F, Keith PK, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239–47. DOI: 10.2500/aap.2011.32.3453
16. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003;33(9):1198–208. DOI: 10.1046/j.1365-2222.2003.01699.x
17. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505. DOI: 10.1034/j.1398-9995.2001.056006498.x
18. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–12. First clinical trial in allergy using the intralymphatic route of administration to enhance allergen-specific immunotherapy. Three low-dose injections with 4-week intervals induced comparable nasal allergen tolerance than 56 high-dose subcutaneous injections over 3 years. DOI: 10.1073/pnas.0803725105
19. Senti G, Crameri R, Kuster D, Johansen P, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–6. Double-blind placebo-controlled clinical trial using modified recombinant Fel d 1 for intralymphatic immunotherapy of cat dander allergic patients. Three intralymphatic injections induced Treg responses and IgG4, resulting in profound nasal allergen tolerance. DOI: 10.1016/j.jaci.2012.02.026
20. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9(6):537–43. DOI: 10.1097/ACI.0b013e3283310ff7
21. Canonica GW, Bousquet J, Casale T, Lockey RF, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64 Suppl 91:1–59.
22. von Moos S, Johansen P, Waeckerle-Men Y, Mohanan D, et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy. 2012;67(5):638–46. DOI: 10.1111/j.1398-9995.2012.02802.x
23. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the ‘epimmunome’. Nat Immunol. 2010;11(8):656–65. DOI: 10.1038/ni.1905
24. Stewart AJ, Devlin PM. The history of the smallpox vaccine. J Infect. 2006;52(5):329–34. DOI: 10.1016/j.jinf.2005.07.021
25. Mitragotri S. Immunization without needles. Nat Rev Immunol. 2005;5(12):905–16. DOI: 10.1038/nri1728
26. Jodar L, Duclos P, Milstien JB, Griffiths E, et al. Ensuring vaccine safety in immunization programmes—a WHO perspective. Vaccine. 2001;19(13–14):1594–605. DOI: 10.1016/S0264-410X(00)00358-3
27. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008;371(9629):2019–25. Double-blind placebo-controlled clinical trial demonstrating clinical efficacy of transcutaneous vaccination using a patch containing antigen. Induction of IgG against a toxin of E. coli is demonstrated, as well a clinical protection against travellers’ diarrhoea. DOI: 10.1016/S0140-6736(08)60839-9
28. Hickey DK, Aldwell FE, Tan ZY, Bao S, et al. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Vaccine. 2009;27(50):6983–90. DOI: 10.1016/j.vaccine.2009.09.078
29. Sullivan SP, Koutsonanos DG, Del Pilar MM, Lee JW, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915–20. DOI: 10.1038/nm.2182
30. Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release. 2009;136(1):71–8. DOI: 10.1016/j.jconrel.2009.01.025
31. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest. 2004;113(7):998–1007. DOI: 10.1172/JCI20261
32. Yagi H, Hashizume H, Horibe T, Yoshinari Y, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res. 2006;66(20):10136–44. DOI: 10.1158/0008-5472.CAN-06-1029
33. Rechtsteiner G, Warger T, Osterloh P, Schild H, et al. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol. 2005;174(5):2476–80.
34. Bynoe MS, Evans JT, Viret C, Janeway Jr CA. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity. 2003;19(3):317–28. DOI: 10.1016/S1074-7613(03)00239-5
35. Bynoe MS, Viret C. Antigen-induced suppressor T cells from the skin point of view: suppressor T cells induced through epicutaneous immunization. J Neuroimmunol. 2005;167(1–2):4–12. DOI: 10.1016/j.jneuroim.2005.06.004
36. Blamoutier P, Blamoutier J, Guibert L. Traitement co-saisonnier de la pollinose par l’application d’extraits de pollens sur des quadrillages cutanés: Résultats obtenus en 1959 et 1960. Rev Fr d’Allergie;1(2):112–120. Early report in large patient numbers using the method of skin scarification before application of allergen extracts to such prepared skin.
37. Vallery-Radot P, Hangenau J. Asthme d’origine équine. Essai de désensibilisation par des cutiréactions répétées. Bull Soc Méd Hôp Paris. 1921;45:1251–60. First report of successful epicutaneous allergen-specific immunotherapy.
38. Hurwitz SH. Medicine: seasonal hay fever-some problems in treatment. Cal West Med. 1930;33(1):520–1.
39. Phillips EW. Relief of hay-fever by intradermal injections of pollen extract. J Am Med Assoc. 1926;86(3):182–4. DOI: 10.1001/jama.1926.02670290022008
40. Pautrizel R, Cabanieu G, Bricaud H, Broustet P. Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route. Sem Hop. 1957;33(22):1394–403.
41. Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med. 1959;67:2299–301.
42. Eichenberger H, Storck H. Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier. Acta Allergol. 1966;21(3):261–7. DOI: 10.1111/j.1398-9995.1966.tb03112.x
43. Martin-DuPan RBF, Neyroud M. Treatment of pollen allergy using the cutaneous checker square method of Blamoutier and Guilbert. Schweiz Rundsch Med Prax. 1971;60(44):1469–72.
44. Palma-Carlos AG. Traitement co-saisonnier des pollinoses au Portugal par la méthode des quadrillages cutanés. Rev Fr d’Allergie;7(2):92–95.
45. Senti G, Graf N, Haug S, Ruedi N, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124(5):997–1002. DOI: 10.1016/j.jaci.2009.07.019
46. Dickel H, Goulioumis A, Gambichler T, Fluhr JW, et al. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin Pharmacol Physiol. 2010;23(5):259–65. DOI: 10.1159/000314700
47. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 1994;30(4):535–46. DOI: 10.1016/S0190-9622(94)70059-1
48. Dickel H, Gambichler T, Kamphowe J, Altmeyer P, et al. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of ‘alarmins’. Contact Dermatitis. 2010;63(4):215–22. DOI: 10.1111/j.1600-0536.2010.01769.x
49. Senti G, von Moos S, Tay F, Graf N, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128–35. This large double-blinded placebo-controlled dose escalation study finds that efficacy of epicutaneous allergen-specific immunotherapy is dose-dependent. DOI: 10.1016/j.jaci.2011.08.036
50. Senti G, et al. manuscript in preparation.
51. Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy. 2010;65(3):410–1. Double-blind placebo-controlled clinical trial in children suffering from grass pollen induced hay fever, using the epicutaneous route for allergen-specific immunotherapy. DOI: 10.1111/j.1398-9995.2009.02189.x
52. Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol 2012;130(4):918–24 -. Interesting study where repeated low-dose intradermal allergen administrations are found to reduce the late cutaneous response of skin prick testing, suggesting that repeated low-dose intradermal administration induced T cell tolerance to the allergen.
53. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, et al. Epicutaneous immunotherapy compared with sublingual immunotherapy in mice sensitized to pollen (Phleum pratense). ISRN Allergy. 2012;2012:375735. DOI: 10.5402/2012/375735
54. Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, et al. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165–7. Clinical pilot trial evaluating transcutaneous cow milk administration for immunotherapy of cow milk allergy. While not reaching statistical significance, a reduction in allergic reactivity against cow milk was observed. DOI: 10.1016/j.jaci.2010.02.029
55. Scurlock AM, Jones SM. An update on immunotherapy for food allergy. Curr Opin Allergy Clin Immunol. 2010;10(6):587–93. DOI: 10.1097/ACI.0b013e32833fd5eb
56. Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy. 2011;66(6):798–809. DOI: 10.1111/j.1398-9995.2011.02560.x
57. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659–67. DOI: 10.1111/j.1365-2222.2009.03430.x
58. Mondoulet L, Dioszeghy V, Vanoirbeek JA, Nemery B, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2010;154(4):299–309. DOI: 10.1159/000321822
59. Kalach N, Soulaines P, de Boissieu D, Dupont C. A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow’s milk allergy in children. J Allergy Clin Immunol. 2005;116(6):1321–6. DOI: 10.1016/j.jaci.2005.08.033
60. Soury D, Barratt G, Ah-Leung S, Legrand P, et al. Skin localization of cow’s milk proteins delivered by a new ready-to-use atopy patch test. Pharm Res. 2005;22(9):1530–6. DOI: 10.1007/s11095-005-5881-4
61. Rattanapak T, Rattanapak T, Birchall J, Birchall J, et al. Transcutaneous immunization using microneedles and cubosomes: Mechanistic investigations using optical coherence tomography and two-photon microscopy. J Control Release;Aug 23.
62. Bal SM, Ding Z, van Riet E, Jiskoot W, et al. Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? J Control Release 2010;Sep 24.
63. Weiss R, Hessenberger M, Kitzmuller S, Bach D, et al. Transcutaneous vaccination via laser microporation. J Control Release. 2012;162(2):391–9. A LASER is used for microporation of the skin in preparation of allergen-specific epicutaneous immunotherapy. DOI: 10.1016/j.jconrel.2012.06.031
64. Scheiblhofer S, Thalhamer J, Weiss R. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin Drug Deliv. 2013;10(6):761–73. DOI: 10.1517/17425247.2013.773970
65. Mondoulet L, Dioszeghy V, Puteaux E, Ligouis M, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Trans Allergy. 2012;2(1):22. DOI: 10.1186/2045-7022-2-22
66. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93. DOI: 10.1038/nri2510
67. Scharton-Kersten T, Yu J, Vassell R, O’Hagan D, et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun. 2000;68(9):5306–13. DOI: 10.1128/IAI.68.9.5306-5313.2000
68. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature. 1998;391(6670):851. DOI: 10.1038/36014
69. Stoitzner P, Sparber F, Tripp CH. Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol. 2010;88(4):431–7. DOI: 10.1038/icb.2010.31
70. Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol. 2006;6(11):869–74. DOI: 10.1038/nri1958
71. Asher MI, Montefort S, Bjorksten B, Lai CK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43. DOI: 10.1016/S0140-6736(06)69283-0
72. Hankin CS, Cox L, Lang D, Bronstone A, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010;104(1):79–85. DOI: 10.1016/j.anai.2009.11.010